Aprinoia Therapeutics (Aprinoia Therapeutics) Total Stockholders Equity : $-81.93 Mil (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Total Stockholders Equity?

Aprinoia Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-81.93 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Aprinoia Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $-2.94. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aprinoia Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2023 was -0.19.

Aprinoia Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Aprinoia Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Total Stockholders Equity Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Total Stockholders Equity

-48.69

-75.45

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Total Stockholders Equity	-48.69	-	-75.45	-81.93

Aprinoia Therapeutics (NAS:APRI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Aprinoia Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-81.932	-	0)	/	27.829
	=	-2.94

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Aprinoia Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.58	+	0.015)	/	-81.932
	=	-0.19

Aprinoia Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines